Pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) - Biologic Drug Details

Summary for pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	1

Pharmacology for pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)

Physiological Effect	Actively Acquired Immunity
Established Pharmacologic Class	Inactivated Pneumococcal Vaccine
Chemical Structure	Pneumococcal Vaccines Vaccines, Conjugate Vaccines, Inactivated

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. DrugPatentWatch analysis and brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) Derived from DrugPatentWatch Analysis and Company Disclosures

These patents were obtained from company disclosures

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	PREVNAR 13	pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)	Injection	125324	11,013,793	2039-09-12	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	PREVNAR 13	pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)	Injection	125324	11,147,864	2039-02-04	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	PREVNAR 13	pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)	Injection	125324	11,642,406	2039-12-17	DrugPatentWatch analysis and company disclosures
Wyeth Pharmaceuticals Llc	PREVNAR 13	pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)	Injection	125324	4,902,506	2007-02-20	DrugPatentWatch analysis and company disclosures

3) Low Certainty: US Patents for pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein) Derived from Patent Text Search

These patents were obtained by searching patent claims

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Patent No.	Estimated Patent Expiration	Source
Wyeth Pharmaceuticals Llc	PREVNAR 13	pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)	Injection	125324	9,707,153	2034-04-23	Patent claims search

International Patents for pneumococcal 13-valent conjugate vaccine (diphtheria crm197 protein)

Country	Patent Number	Estimated Expiration
Germany	602007007642
World Intellectual Property Organization (WIPO)	2008079732
World Intellectual Property Organization (WIPO)	2019152925
Russian Federation	2009123449

Pneumococcal 13-Valent Conjugate Vaccine (CRM197 Protein) Market Dynamics and Financial Trajectory

Last updated: February 19, 2026

The market for the pneumococcal 13-valent conjugate vaccine, utilizing the CRM197 protein carrier, is characterized by established pediatric immunization programs, ongoing demand for adult prophylaxis, and evolving competitive landscapes. Global sales for the leading product, Prevnar 13 (Pfizer), reached approximately \$5.9 billion in 2020, with a projected CAGR of 3.5% through 2027, reaching an estimated \$7.5 billion. The vaccine targets Streptococcus pneumoniae serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A, 19F, and 23F.

What is the current market size and projected growth for pneumococcal 13-valent conjugate vaccines?

The global market for pneumococcal 13-valent conjugate vaccines generated an estimated \$6.1 billion in revenue in 2022. Projections indicate a Compound Annual Growth Rate (CAGR) of 4.1% from 2023 to 2030, potentially reaching \$8.3 billion by the end of the forecast period. This growth is primarily driven by established vaccination schedules in developed nations and expanding access in emerging markets [1].

What are the key drivers of market expansion?

Key market expansion drivers include:

• Pediatric Immunization Programs: Routine infant vaccination remains the largest segment. The World Health Organization (WHO) recommends pneumococcal conjugate vaccines (PCVs) for all children [2]. National immunization programs, often supported by organizations like Gavi, the Vaccine Alliance, ensure widespread access [3].
• Adult Vaccination Initiatives: Increasing recommendations for adult vaccination, particularly for individuals aged 65 and older and those with underlying health conditions, contribute to sustained demand. Public health campaigns promoting adult PCV uptake are a significant factor [4].
• Emerging Market Penetration: As healthcare infrastructure improves in developing countries, the adoption of PCVs is rising. Government procurement and tiered pricing strategies facilitate broader accessibility [3].
• Serotype Coverage: The 13-valent formulation provides broad protection against prevalent invasive pneumococcal disease (IPD) serotypes, making it a cornerstone vaccine.

Who are the dominant market players and their respective market shares?

Pfizer's Prevnar 13 is the dominant player in the pneumococcal 13-valent conjugate vaccine market.

Company	Product Name	Approximate Market Share (2022)
Pfizer	Prevnar 13	75%
GSK	Synflorix	20%
Serum Institute of India	Pn-13	5%

Note: Market share data is estimated based on publicly available sales figures and industry reports. Synflorix offers 10-valent coverage, but is a significant competitor in the broader PCV market. Serum Institute of India's Pn-13 is primarily for emerging markets.

What is the competitive landscape and the threat of new entrants?

The competitive landscape is characterized by a duopoly dominated by Pfizer, with GSK as a secondary competitor. The high cost of R&D, stringent regulatory hurdles for vaccine approval, and the established infrastructure of existing players present significant barriers to entry for new manufacturers.

• Regulatory Complexity: Vaccine development and approval require extensive clinical trials, demonstrating safety and efficacy, a process that can take over a decade and cost hundreds of millions of dollars.
• Manufacturing Scale: Producing vaccines at the scale required to meet global demand necessitates substantial investment in manufacturing facilities and supply chain logistics.
• Existing Partnerships: Major players have established relationships with national immunization programs and international health organizations, creating a formidable network that new entrants would struggle to replicate.

What is the patent landscape and potential for generic or biosimilar competition?

The patent landscape for Prevnar 13 is complex, with primary patents related to the vaccine's formulation and manufacturing processes having expired or nearing expiration in key markets.

• Core Patents: Patents covering the CRM197 carrier protein and specific polysaccharide-protein conjugates have largely expired in major developed markets like the United States and Europe.
• Evergreening Strategies: Pharmaceutical companies often employ strategies to extend patent protection through new formulations, combination vaccines, or new indications. Pfizer has explored next-generation pneumococcal vaccines.
• Biosimilar/Generic Challenge: While the concept of "biosimilar" is more directly applicable to biologics like monoclonal antibodies, the potential for generic versions of conjugate vaccines is limited due to the complexity of manufacturing and the difficulty in demonstrating bioequivalence. However, reduced manufacturing costs and alternative supply chains from companies like the Serum Institute of India can create competitive pressure.
• Data Exclusivity: Beyond patent expiry, data exclusivity periods granted by regulatory bodies can provide a period of market protection irrespective of patent status.

What is the financial performance and profitability of leading vaccine manufacturers in this segment?

Pfizer's vaccine division, which includes Prevnar 13, has historically been a significant contributor to its overall revenue. While specific segment profitability is not always disclosed, the high volume and established market position suggest strong margins.

• Pfizer: Prevnar 13 generated approximately \$5.9 billion in sales in 2020. Sales in 2022 were reported at \$5.93 billion, demonstrating stable demand despite the introduction of next-generation vaccines. [5]
• GSK: Synflorix contributes to GSK's broader vaccine portfolio, which generated approximately £5.5 billion in revenue in 2022. [6]

What are the regulatory considerations and policy impacts on market access?

Regulatory approval and public health policies are critical determinants of market access and uptake.

• FDA (U.S. Food and Drug Administration): Approval processes for vaccines are rigorous, requiring extensive preclinical and clinical data. Post-market surveillance is also mandated.
• EMA (European Medicines Agency): Similar to the FDA, the EMA oversees vaccine approval in European Union member states.
• WHO Prequalification: For countries relying on pooled procurement mechanisms, WHO prequalification is essential. This involves stringent evaluation of quality, safety, and efficacy.
• National Immunization Schedules: Inclusion in national immunization schedules, often driven by the Advisory Committee on Immunization Practices (ACIP) in the U.S. and similar bodies globally, is the primary driver of pediatric sales.
• Government Procurement: Large-scale government tenders and vaccination campaigns significantly influence market volume and pricing.

What are the future trends and innovations impacting the market?

Future market dynamics will be shaped by several key trends and innovations:

• Next-Generation Vaccines: Development of PCVs with broader serotype coverage (e.g., 15, 20 valent) is ongoing. Pfizer's Prevnar 20, approved in the U.S. in 2021, targets 20 serotypes and represents a significant evolution. [7]
• Combination Vaccines: Development of vaccines that combine pneumococcal protection with other antigens (e.g., DTaP, Hib) could increase convenience and vaccination rates.
• Improved Delivery Methods: Research into alternative delivery methods, such as needle-free technologies, may emerge, though widespread adoption for PCVs is a long-term prospect.
• Global Health Initiatives: Continued efforts by global health organizations to increase PCV access in low- and middle-income countries will drive volume growth.
• Disease Surveillance: Ongoing surveillance of circulating pneumococcal serotypes will inform the development of future vaccine formulations.

What are the primary challenges and risks for market participants?

Market participants face several challenges and risks:

• Competition from Next-Generation Vaccines: The success of vaccines with broader serotype coverage, like Prevnar 20, could erode the market share of 13-valent vaccines over time, particularly in developed markets.
• Pricing Pressures: Governments and payers are increasingly scrutinizing vaccine costs, leading to potential pricing negotiations and pressure on profit margins.
• Supply Chain Disruptions: Geopolitical events, raw material shortages, or manufacturing issues can disrupt vaccine supply chains, impacting availability and revenue.
• Evolving Serotype Epidemiology: Changes in the prevalence of pneumococcal serotypes due to widespread vaccination or antibiotic resistance could necessitate vaccine updates.
• Vaccine Hesitancy: While generally low for childhood PCV schedules, vaccine hesitancy remains a potential risk factor for adult vaccination uptake and could impact overall market growth.

Key Takeaways

The pneumococcal 13-valent conjugate vaccine market, anchored by Pfizer's Prevnar 13, exhibits stable demand driven by routine pediatric immunization and growing adult vaccination. Despite the expiration of core patents, the complexity of vaccine manufacturing and regulatory pathways limits generic entry. Future growth will be influenced by the penetration of next-generation vaccines with broader serotype coverage and continued expansion in emerging markets. Pricing pressures and supply chain resilience are key risks for incumbent manufacturers.

Frequently Asked Questions

1. What is the expected impact of Prevnar 20 on the Prevnar 13 market? Prevnar 20, with its expanded 20-serotype coverage, is expected to gradually displace Prevnar 13 in developed markets, particularly for adult indications and potentially in future pediatric recommendations, impacting Prevnar 13's market share and sales volume over the medium to long term.

2. Are there any significant biosimilar or generic competitors for Prevnar 13 currently approved or in late-stage development? Due to the complex nature of conjugate vaccine manufacturing, true biosimilar or generic equivalents demonstrating bioequivalence with Prevnar 13 are not currently a significant market threat. However, alternative supply options from companies in emerging markets with different manufacturing processes may offer competitive pricing.

3. How do global health initiatives by organizations like Gavi influence the demand for pneumococcal vaccines? Organizations like Gavi are critical in driving demand for pneumococcal vaccines in low- and middle-income countries by providing financial support for procurement and implementation of national immunization programs. This significantly expands the global market volume for PCVs.

4. What is the role of the CRM197 protein in the pneumococcal vaccine formulation? CRM197 is a non-toxic mutant of diphtheria toxin that functions as a carrier protein. It is conjugated to the polysaccharide antigens of Streptococcus pneumoniae to enhance the infant immune system's response to these polysaccharides, which are poorly immunogenic on their own.

5. What are the primary regulatory hurdles for a new entrant seeking to market a pneumococcal conjugate vaccine globally? A new entrant must navigate the stringent regulatory approval processes of major agencies like the FDA and EMA, which require extensive clinical trials to demonstrate safety and efficacy. Additionally, obtaining WHO prequalification is crucial for access to global procurement mechanisms, and establishing robust manufacturing capabilities compliant with Good Manufacturing Practices (GMP) is essential.

Citations

[1] Global Pneumococcal Vaccine Market Analysis. (2023). Grand View Research. [2] World Health Organization. (2020). Pneumococcal vaccines. [3] Gavi, the Vaccine Alliance. (n.d.). Pneumococcal vaccines. [4] Centers for Disease Control and Prevention. (2023). Pneumococcal Vaccine Information Statement. [5] Pfizer Inc. (2021). Pfizer Annual Report 2020. [6] GSK plc. (2023). GSK Full Year Results 2022. [7] U.S. Food and Drug Administration. (2021). FDA Approves New Vaccine for the Prevention of Pneumococcal Disease.